New hope for HIV patients with Hard-to-Treat hepatitis c
NCT ID NCT01332955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a combination of three drugs—telaprevir, peginterferon, and ribavirin—in 70 adults with both HIV and hepatitis C who had not been helped by standard treatment before. The goal was to see if this triple therapy could clear the hepatitis C virus from the body for good. Participants took the drugs for up to 72 weeks, and the main measure of success was whether the virus stayed undetectable 24 weeks after treatment ended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- telaprevir, peginterferon alfa-2a, and ribavirin
- What this could lead to
- If successful, this could offer a new treatment option for HIV-HCV coinfected patients who have not responded to standard therapy, potentially clearing the hepatitis C virus.
- What could go wrong
- This is a small, early-phase pilot study with only 70 participants. The treatment involves multiple drugs with known side effects, and the success rate may still be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse
Lyon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
- Immune-Boosting cocktail aims to free HIV patients from daily medication